Turmeric and its components have various health beneficial functions. However, little is known about function of bisacurone, which is one of the sesquiterpenes in turmeric, at the compound level. In this study, we investigated the preventive effect of bisacurone on hepatic lipid accumulation and its mechanism in HepG2 cells and ICR mice. In HepG2 cells, bisacurone significantly inhibited fatty acid-induced intracellular lipid accumulation in a dose-dependent manner. Bisacurone at 10 μM increased expression of peroxisome proliferator-activated receptor α and carnitine palmitoyltransferase-1A accompanied by phosphorylation of AMP-activated protein kinase. In the liver of ICR mice, bisacurone decreased total lipids, triglyceride, and cholesterol contents. Bisacurone at 10 mg/kg body weight increased phosphorylation of AMP-activated protein kinase, and its downstream acetyl-CoA carboxylase as a rate-limiting enzyme for lipogenesis, while it decreased the nuclear translocation level of sterol regulatory element-binding protein 1 and carbohydrate-responsive element-binding protein as the major transcription factors for lipogenesis. On the other hand, bisacurone promoted lipolysis by up-expression of peroxisome proliferator-activated receptor α and carnitine palmitoyltransferase-1A. Thus, bisacurone might be a valuable food factor for preventing hepatic lipid accumulation by inhibiting lipogenesis and promoting lipolysis through phosphorylation of AMP-activated protein kinase.

**Key Words:** bisacurone, turmeric, lipid metabolism, AMP-activated protein kinase, liver

**Introduction**

Excess accumulation of lipids in the liver is currently recognized as the most common cause of chronic liver diseases and a risk factor for other diseases.\(^1\) In the liver, lipid accumulation results from an imbalance between increasing lipogenesis and decreasing lipolysis including fatty acid oxidation.\(^2\)\(^-\)\(^4\) This imbalance tilted toward to the lipid accumulation causes hepatic steatosis, hyperlipidemia, cardiovascular disease, obesity, and diabetes.\(^5\) AMP-activated protein kinase (AMPK), a serine/threonine protein kinase, plays a key role in energy homeostasis including hepatic lipid metabolism, serving as a metabolic master switch in response to alterations in cellular energy charge.\(^6\) Recent studies have showed that liver kinase B1 (LKB1), a 50 kDa serine/threonine kinase, is one of the important upstream kinases of AMPK. LKB1 can activate AMPK by phosphorylation at Thr172 in mammalian cells. This activation of AMPK is involved in various pathways such as fatty acid, triglyceride, and cholesterol synthesis as well as catabolic pathways such as lipolysis and fatty acid oxidation.\(^7\) Based on this, AMPK-mediated pathways have emerged as the novel targets for the treatment of obesity and fatty liver.\(^8\)

AMPK modulates lipid synthesis, lipolysis, and fatty acid oxidation through phosphorylation of key substrates, acetyl-CoA carboxylase (ACC), and sterol regulatory element binding protein 1 (SREBP-1).\(^9\) Inactivation of ACC by its phosphorylation results in an increase in fatty acid oxidation and suppression of fatty acid synthesis, while phosphorylation of SREBP-1 decreases its nuclear translocation resulting in down regulating the expression of lipogenic enzymes, including ACC and fatty acid synthase (FAS).\(^10\) Transcriptional factors, such as carbohydrate-responsive element-binding protein (ChREBP), peroxisome proliferator-activated receptor (PPAR) α and CCAAT/enhancer binding protein (C/EBP) α also regulate lipolysis and fatty acid oxidation in the liver. ChREBP and C/EBPα induce fatty acid synthesis through the induction of lipogenic genes, such as FAS and ACC, whereas activation of PPARα increase fatty acid oxidation.\(^11\)\(^-\)\(^13\) These transcriptional responses also occur in large part through the activation of AMPK.\(^14\)

Turmeric (Curcuma longa L.) is a traditional Indian food spice which is also widely used as folk medicine.\(^15\) Curcumin is well-documented active compound in turmeric and possesses various health beneficial functions.\(^16\)\(^-\)\(^19\) In addition to curcuminoids, turmeric contains various sesquiterpenes, such as bisacurone, turmerones (ar-, α-, and β-), turmeronol (A and B), and curcumenol.\(^20\)\(^21\) It was reported that certain sesquiterpenes also possesses health beneficial functions at compound level experiments.\(^22\)\(^-\)\(^24\) However, it has little known about the function of bisacurone at a compound level, though one previous report demonstrates bisacurone inhibits adhesion of inflammatory monocytes and oral cancer cells to human umbilical vein endothelial cells through down-regulation of vascular adhesion molecule-1.\(^25\)

An aim of this study is investigation of the reduction of hepatic lipid accumulation by bisacurone at the compound level. First, the authors examined the prevention effect of bisacurone on saturated fatty acids-induced lipid accumulation in HepG2. Next, the authors carried out animal experiment using ICR mice to clarify the effects of oral administrated bisacurone on hepatic lipid accumulation in vivo. To clarify the underlying molecular mechanisms, the authors focused on the AMPK-driven pathways and investigated the effects of bisacurone on lipogenesis- and lipolysis-related factors in the liver.

**Materials and Methods**

**Reagents.** Bisacurone was purchased from Nagara Science Co., Ltd. (Gifu, Japan). Curcumin, palmitic acid, oleic acid, and ImmunoStar LD was purchased from FUJIFILM Wako Pure Chemical Industries (Osaka, Japan). Their chemical structures are shown in Fig. 1. Metformin hydrochloride was from Sigma-Aldrich.
was obtained from Nissui Pharmaceutical (Tokyo, Japan). Bovine serum albumin (BSA), Blocking One, and Blocking One-P solutions were from Nacalai Tesque, Inc. (Kyoto, Japan). For western blotting, antibodies for lamin B, PPARα, CPT1, fatty acid binding protein 4 (FABP4), C/EBPα, FAS, anti-mouse IgG, anti-goat IgG, and anti-rabbit IgG were purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA); β-actin, p-AMPKα, AMPKα, p-LKB1, and LKB1 were from Cell Signaling Technology (Beverly, MA); ChREBP and SREBP-1 from Abcam (Cambridge, MA). The polyvinylidene difluoride membrane was products of GE Healthcare Bio-Science Co., (Piscataway, NJ). All other reagents used were of the highest grade available from commercial sources.

Cell culture and treatments. HepG2 cells were maintained and cultured in Dulbecco’s modified Eagle’s medium (Nissui Pharmaceutical, Tokyo, Japan) containing 10% (v/v) fetal bovine serum (Sigma-Aldrich), 4 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin under a humidified atmosphere of 95% (v/v) air and 5% (v/v) CO₂ at 37°C. The cells were grown to 80% confluence and incubated in serum-free medium overnight before treatment. The cells were simultaneously treated with 1.2 mM fatty acids mixture (palmitic acid:oleic acid = 1:2 ratio) and various concentrations of bisacurone and curcumin for 24 h.

The inhibitory effect of bisacurone on the lipid accumulation in vitro, HepG2 cells were cultured in serum-free medium overnight and then exposed to a mixture of 1.2 mM fatty acids (palmitic acid:oleic acid = 1:2 ratio) with or without 0.01, 0.1, 1.0, and 10 μM of bisacurone for 24 h. Sudan II staining was carried out to determine intracellular lipid accumulation according to the previous report. The result of cell viability was expressed as percent of control cells.

Determination of intracellular lipid content in HepG2 cells. The inhibitory effect of bisacurone on the lipid accumulation in vitro, HepG2 cells were cultured in serum-free medium overnight and then exposed to a mixture of 1.2 mM fatty acids (palmitic acid:oleic acid = 1:2 ratio) with or without 0.01, 0.1, 1.0, and 10 μM of bisacurone for 24 h. Sudan II staining was carried out to determine intracellular lipid accumulation according to the previous report.

Animal experiments. For the animal experiments, thirty-six ICR male mice (5-week-old) mice (Japan SLC, Inc., Shizuoka, Japan) were used to assess the effects of bisacurone on lipid metabolism. Animal experiments were approved by the Kobe University Institutional Animal Care and Use Committee (Permission 28-12-01) and carried out in accordance with the guidelines for animal experiments at Kobe University Animal Experimentation Regulation. Mice were randomly divided to six groups of six each and acclimatized for 7 days with free access to a standard diet (3.85 kcal/g) consisting of 76% (w/w) carbohydrate, 15% (w/w) protein, and 9% (w/w) fat (Research Diets, Tokyo, Japan) and tap water. They were orally administered with 0.1, 1, or 10 mg/kg body weight (BW) of bisacurone, 10 mg/kg BW of curcumin, 200 mg/kg BW of metformin as a positive control, and polyethylene glycol as a negative control for another 7 consecutive days. Blood, liver, and perirenal, epididymis, mesenteric and subcutaneous white adipose tissues were collected 24 h after the final administration.

Measurement of hepatic lipid levels. The hepatic lipids were extracted by the method of Folch et al. Briefly, an aliquot of approximately 100 mg of liver was homogenized with 0.35 ml of distilled water. Lipids in the homogenates were extracted 3 times with 0.7 ml of a chloroform/methanol (2/1, v/v) solution. After centrifugation at 1,800 x g for 10 min, the chloroform layers were collected, and a one-fourth volume of 0.88% (w/v) KCl solution was added. The mixtures were vortexed and centrifuged at 1,800 x g for 10 min; the chloroform layers were then collected and evaporated, and the weight of the residue was measured as total lipid. The residue was dissolved in isopropanol containing 10% (v/v) Triton-X and subjected to the measurement of triglyceride and cholesterol levels using corresponding commercial kits from FUJIFILM Wako Pure Chemical Industries according to the manufacturer’s instructions.

Measurement of plasma lipids. Blood was centrifuged at 9,600 x g for 10 min at 4°C. The supernatant was collected and used as the plasma for measurement of cholesterol and triglyceride levels using the same commercial kits as mentioned above.

Western blot analysis. Preparation of lysate and the subcellular fractions from HepG2 cells and the liver of ICR mice and western blotting were performed according to our previous report. For the determination of SREBP-1 and ChREBP, proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 8% gels. For p-LKB1, LKB1, p-AMPKα, AMPKα, p-ACCα, ACC, PPARα, CPT1, C/EBPα, FAS, FABP4, lamin B, and β-actin, SDS-PAGE was carried out onto a polyvinylidene fluoride membrane. The membrane was treated with blocking buffer [Blocking One or Blocking One P (for phosphorylated protein)] for 1 h at room temperature. Then, the membranes were incubated with appropriate primary antibody for p-LKB1 (1:5,000), LKB1 (1:10,000), p-AMPKα (1:5,000), AMPKα (1:10,000), p-ACCα (1:5,000), ACCα (1:10,000), PPARα (1:5,000), CPT1 (1:5,000), C/EBPα (1:5,000), FAS (1:5,000), FABP4 (1:5,000), SREBP-1 (1:5,000), ChREBP (1:5,000), lamin B (1:10,000), and β-actin (1:10,000) overnight at 4°C, followed by the corresponding HRP-conjugated secondary antibody (1:10,000) for 2 h at 4°C. The protein bands were visualized using ImmunoStar® LD and specific immune complexes were detected with the ATTO Light-Capture II Western Blotting Detection System (ATTO, Tokyo, Japan).
density of specific band was analyzed using ImageJ analysis software (National Institutes of Health, Bethesda, MD).

**Statistical analysis.** The data are expressed as the mean ± SE. Dunnett’s test was used to determine the significance of differences between the treated and control groups. The level of statistical significance was set to *p*<0.05.

**Results**

**Effects of turmeric compounds on cell viability in HepG2 cells.** Cell viability was estimated by the crystal violet staining assay after treatment with indicated concentrations of bisacurone and curcumin for 24 h (Fig. 2). Bisacurone did not show any cytotoxicity by 10 μM, whereas curcumin at 10 μM slightly but significantly exhibited cytoxicity. α-Curcumene and ar-tumerone, other sesquiterpenes in turmeric, also did not show the cytotoxicity by 10 μM (data not shown). Therefore, bisacurone was treated to the cells at 0.01, 0.1, 1.0, and 10 μM of the following experiments.

**Bisacurone inhibited fatty acids-induced cellular lipid accumulation in HepG2 cells.** In our previous study, the mixtures of 1:2 proportions of palmitic acid and oleic acid significantly increased lipid accumulation in HepG2 cells.(27) Under the same experimental conditions, we examined whether bisacurone inhibited fatty acids-induced cellular lipid accumulation in HepG2 cells. As shown in Fig. 3, the result from Sudan II staining showed that the mixtures of saturated fatty acids significantly increased lipid accumulation and metformin (2.0 mM) as a dose-dependent manner, and the significant increase was observed at 10 μM. It was confirmed that the fatty acids mixture alone did not affect the expression of PPARα and CPT1. These results indicate that bisacurone increased lipolysis through phosphorylation of ACCα.

As to the lipolytic pathway, we focused on two important factors, PPARα and CPT1, which are involved in hepatic fatty acid oxidation and lipolysis, respectively.(13) As shown in Fig. 5, bisacurone increased expression of PPARα (Fig. 5A) and CPT1 (Fig. 5B) in a dose-dependent manner, and the significant increase was observed at 10 μM. It was confirmed that the fatty acids mixture alone did not affect the expression of PPARα and CPT1. These results indicate that bisacurone increase lipolysis through promotion of fatty acids oxidation.

**Changes in the body and tissue weights and plasma lipids of mice after oral administration of bisacurone for 7 days.** Next, we explored the *in vivo* experiment to investigate the effects of bisacurone on hepatic lipid metabolism. Orally administered bisacurone for 7 consecutive days did not affect body and liver weight in all experimental groups (Table 1). Weight of white and brown adipose tissues did not alter in all groups, except mesenteric fat of the mice given bisacurone at 1 mg/kg BW. Moreover, there was no change in the levels of plasma triglyceride and total cholesterol (data not shown). These results suggested that an intake of bisacurone did not show the toxicity to the mice under our experimental conditions.

**Oral administration of bisacurone decreased total lipid content, triglyceride, and total cholesterol in the liver of mice.** Although there was no change in the liver weight among all the groups (Table 1), oral administration of bisacurone decreased total lipid content at 10 mg/kg BW in the liver (Fig. 6). The level of triglyceride decreased in the groups of bisacurone at 1.0 and 10 mg/kg BW, and the level of total cholesterol also decreased in all bisacurone-dosed groups. The curcumin given group also decreased total lipid content, triglyceride and cholesterol levels in
the liver. Interestingly, the metformin group showed a decrease in total cholesterol level in the liver, but there were no change in the total lipid content and triglyceride level. These results suggested that bisacurone and curcumin possible to reduce hepatic lipid storage without affecting plasma lipids.

**Effects of oral administration of bisacurone on lipogenesis in the liver of mice.** Since AMPK modulates lipogenesis synthesis, lipolysis, and fatty acid oxidation, it was investigated that phosphorylation of AMPKα and its downstream lipogenesis enzyme ACC and upstream kinase LKB1. As shown in Fig. 7, administration of bisacurone at 1.0 and 10 mg/kg BW significantly increased the phosphorylation levels of AMPKα, ACCα, and LKB1 in the liver of mice. The similar results were observed in the curcumin- and metformin-given groups, except curcumin failed increased LKB1 phosphorylation. As the downstream events for the AMPK activation, the nuclear translocation levels of SREBP-1 and ChREBP in the liver were measured (Fig. 8A). Administration of bisacurone decreased the nuclear levels of SREBP-1 and ChREBP in a dose-dependent manner, and significant decreased was observed at 1.0 and 10 mg/kg BW. Curcumin and metformin also decreased them. On the other hand, these compounds did not affect the levels of SREBP-1 and ChREBP in the post-nuclear fraction (data not shown). Since FAS and C/EBPα are involved in hepatic lipid accumulation, their expression levels were further examined in this study. It was found that bisacurone significantly decreased the expression level of FAS and C/EBPα in the liver (Fig. 8B). Curcumin and metformin also decreased their expression levels. These results strongly suggest that bisacurone can reduced the lipogenesis in the liver not only through the regulation of phosphorylation of AMPKα/
ACCα pathway but also through the decrease in nuclear translocation of the transcriptional factors, SREBP and ChREBP.

**Effects of oral administration of bisacurone on lipolysis in the liver of mice.** As to the lipolysis factors, we investigated the expression of PPARα and CPT1 and found that Bisacurone at 1.0 and 10 mg/kg BW significantly increased the expression level of PPARα and CPT1 in the liver. Curcumin, but not metformin, also showed the similar effects. It was reported that Fatty acid binding protein 4 (FABP4) is a target gene of PPARα.[30] Therefore, we further investigated the expression level of FABP4. It was found that the expression level of FABP4 was similar to that of PPARα and CPT1, i.e., bisacurone and curcumin, but not metformin, increased the FABP4 expression.

**Table 1. Changes in the body and tissue weight after administration of bisacurone, curcumin, and metformin for 7 days**

|                      | Control                  | Metformin (mg/kg BW) | Bisacurone (mg/kg BW) | Curcumin (mg/kg BW) |
|----------------------|--------------------------|----------------------|-----------------------|---------------------|
|                      |                          | 200                  | 0.1                   | 1                   | 10                   | 10       |
| Body weight (g)      | 27.76 ± 0.55             | 28.25 ± 0.94         | 28.63 ± 0.70          | 27.35 ± 0.80        | 28.03 ± 0.71         | 27.68 ± 0.46 |
| Liver weight (% of body weight) | 5.99 ± 0.28             | 6.27 ± 0.20          | 6.40 ± 0.13           | 6.61 ± 0.49         | 6.68 ± 0.18          | 6.37 ± 0.23  |
| White adipose tissue weight (% of body weight) |                      |                      |                       |                     |                     |           |
| Epididymis           | 1.53 ± 0.09              | 1.61 ± 0.10          | 1.48 ± 0.07           | 1.22 ± 0.16         | 1.40 ± 0.16          | 1.25 ± 0.22  |
| Perirenal            | 0.44 ± 0.03              | 0.42 ± 0.03          | 0.38 ± 0.02           | 0.32 ± 0.07         | 0.39 ± 0.06          | 0.33 ± 0.06  |
| Mesenteric           | 0.91 ± 0.07              | 0.84 ± 0.13          | 0.74 ± 0.05           | 0.51 ± 0.10*        | 0.72 ± 0.09          | 0.65 ± 0.15  |
| Subcutaneous         | 3.26 ± 0.25              | 3.18 ± 0.44          | 2.95 ± 0.17           | 2.44 ± 0.47         | 2.58 ± 0.56          | 2.46 ± 0.38  |
| Total                | 6.13 ± 0.31              | 6.04 ± 0.65          | 5.54 ± 0.14           | 4.49 ± 0.75         | 5.09 ± 0.78          | 4.70 ± 0.71  |
| Brown adipose tissue weight (% of body weight) | 0.41 ± 0.04              | 0.38 ± 0.03          | 0.48 ± 0.08           | 0.39 ± 0.04         | 0.42 ± 0.05          | 0.40 ± 0.04  |

*Significant difference against control group (p<0.05) by Dunnett's test. BW, body weight.

**Fig. 6.** Effects of bisacurone on the hepatic lipid content in mice. Mice were administrated with 0.1, 1, or 10 mg/kg BW bisacurone and 10 mg/kg BW curcumin for 7 consecutive day. Metformin at 200 mg/kg BW and polyethylene glycol were used as the positive and negative controls, respectively. (A) Total lipids contents, and (B) triglyceride and (C) total cholesterol levels were measured as described in the Material and Methods section. Data are the mean ± SE (n = 6). Statistical analysis was performed using Dunnett’s test. *p<0.05 vs DMSO-treated control cells.
Discussion

In this study, we demonstrated that bisacurone, which is one of the sesquiterpenes in turmeric, prevented hepatic lipid accumulation in HepG2 cells and modulates lipid metabolism in the liver of ICR mice at the compound level. In HepG2 cells, bisacurone inhibited saturated fatty acids-induced lipid accumulation (Fig. 3) through AMPK-driven pathways, i.e., inhibiting lipogenesis through phosphorylation of ACC (Fig. 4) and promoting lipolysis and fatty acid oxidation through upregulation of PPARα and CPT1 (Fig. 5). In the liver of mice, bisacurone also inhibited lipogenesis through the nuclear translocation of SREBP-1 and ChREBP, and downregulation of C/EBPα and FAS (Fig. 8), in addition to phosphorylation of ACC by AMPK (Fig. 7). On the other hand, bisacurone enhanced lipolysis in the liver of mice, accompanied by increasing PPARα, CPT1, and FABP4 (Fig. 9). Taken these results together, a speculated mechanism is shown in Fig. 10. This is the first report that bisacurone attenuated hepatic lipids by modulating lipid metabolism.

It is known that curcumin, a major polyphenolic constituent of turmeric, has been reported to modulate lipid metabolism, but little is known about the health beneficial functions of bisacurone at the compound level. Only one report demonstrated that bisacurone inhibited adhesion of inflammatory monocytes...
and oral cancer cells to human umbilical vein endothelial cells through down-regulation of tumor necrosis factor α-activated vascular adhesion molecule-1, suggesting that bisacurone has the potential to suppress inflammation. Another sesquiterpene, ar-turmerone also suppressed inflammation by inhibiting tumor necrosis factor α-induced phosphorylation of IκBα and NFκB p65 subunit. Hot water extract of Curcuma longa L. (WEC), which is rich in sesquiterpenes including bisacurone and poor in curcuminoids, revealed the similar effect. Recently, WEC was reported to improve inflammation in subject with overweight or pre- or mild hypertension by a randomized, double-blind, placebo controlled trial. WEC was also reported to inhibit hepatic oxidative stress and inflammation, resulting in suppressing acute ethanol-induced liver injury in mice and non-alcoholic steatohepatitis. The former report demonstrated that WEC prevented the ethanol-increased formation of lipid droplets, though there is no quantified data, whereas the latter report showed that intake of WEC did not alter hepatic triglyceride and total cholesterol. Therefore, there is no consistency about the effects of WEC on hepatic lipid accumulation. Moreover, the active compound in WEC is unclear. However, from the results in these previous studies, a clue arises that bisacurone has a potency to prevent nonalcoholic fatty liver disease and can be an active compound in WEC. Although our findings clearly demonstrate that purified bisacurone decreased hepatic triglyceride and total cholesterol levels, there is a limitation of the results that decreasing hepatic lipid accumulation has been estimated in mice fed standard diet, but not high-fat diet. Further study is needed to clarify whether bisacurone also prevents fat accumulation in the liver of obesity model animals including high-fat diet-caused obese animals.

The underlying mechanism of bisacurone on decreasing hepatic lipids is mainly mediated by AMPK-driven pathways. Bisacurone decreased lipogenesis in saturated fatty acids-treated HepG2 cells and the liver of ICR mice accompanied by promoting phosphorylation of ACC, as a target of AMPK (Fig. 4 and 7). Furthermore, bisacurone decreased the nuclear translocation of SREBP-1 and ChREBP, and their target gene, FAS (Fig. 8). SREBP-1 is synthesized as precursor protein that is inserted into the endoplasmic reticulum membrane. The precursor SREBP-1 undergoes proteolytic processing to release the transcriptionally active N-terminal domain, subsequently translocate into the nucleus and promotes its target genes. Previous study has demonstrated that the

![Figure 8](image-url)
increased phosphorylation of AMPK promotes the phosphorylation of SREBP-1 (Ser372), which inhibits the cleavage and nuclear translocation of SREBP-1, thereby reducing transcriptional activity and the expression target genes. 

In addition to AMPK, PPARα also inhibits both the expression and cleavage of SREBP-1. Lee et al. reported that PPARα suppresses SREBP-1 processing through inducing its target, insulin induced gene 2α, which binds to SREBP-1 and prevents translocation of SREBP-1 to the Golgi apparatus during nutrient starvation in the liver. The activity of ChREBP is also reduced by both AMPK and PPARα. These results indicate that bisacurone decreased the expression of lipogenic proteins FAS and ACC through AMPK- and PPARα-mediated SREBP-1- and ChREBP-pathways in the liver. In addition to these pathways, bisacurone decreased the expression of C/EBPα that regulates lipogenesis in the liver. It is reported that C/EBPα knockout mice revealed significant reduction of hepatic triglyceride level by down-regulating lipogenic genes despite obesity. In 3T3-L1 cells, AMPK activator, AICAR, reduced the expression of C/EBPα, suggesting activation of AMPK downregulates the expression of C/EBPα. This report supports our findings that bisacurone activated AMPK pathway and decreased the expression of C/EBPα.

PPARα plays both inhibiting the lipogenesis and promoting the lipolysis in the liver. In the present study, we found that bisacurone increased PPARα at the protein expression level in both fatty acids-treated HepG2 cells (Fig. 5) and in the liver of ICR mice (Fig. 9). The expression and activity of PPARα are regulated various kinds of signaling pathways, including AMPK-pathway. Fasting-activated AMPK by a high AMP/ATP ratio leads to increase the PPARα activity in hepatocytes, while glucose-caused inactivation of AMPK suppresses the gene expression of PPARα in β-cells. On the other hand, the activity of PPARα is decreased by ChREBP. These results are in agreement with our findings that bisacurone increased the phosphorylation of AMPK and the expression of PPARα, and suppressed the nuclear translocation of ChREBP. The activity of CPT-1, the downstream target protein of PPARα, is regulated by AMPK. Phosphorylation of ACC by AMPK leads to inhibit the ACC activity and decrease the content of malonyl-CoA, resulting an increase in the CPT-1 activity through cancelling the inhibitory effect of malonyl-CoA against CPT-1. Taken together, these results suggest that bisacurone-promoted phosphorylation of AMPK is involved in both inhibiting lipogenesis and promoting lipolysis. Meanwhile, metformin did not affect the expression of PPAR and its targets, CPT1 and FABP4 in the liver (Fig. 9). In general, metformin-treated mice increase phosphorylation of AMPK and lipolysis in the liver, but several previous studies reported that short-term treatment of metformin did not affect the lipolysis in the liver of mice and cultured hepatocytes.

Although both bisacurone and curcumin increased phosphorylation of AMPK and its substrate, ACC, bisacurone but not curcumin promoted phosphorylation of LKB1 as an upstream
kinase (Fig. 7). This discrepancy suggest that the molecular target of bisacurone is different from that of curcumin. It is known that both LKB1 and calcium/calmodulin-dependent protein kinase kinase (CaMKK) are involved in AMPK activation. Previous study reported that curcumin analogue, dibenzoylmethane increased phosphorylation of AMPK and CaMKK inhibitor decreased dibenzoylmethane-induced phosphorylation in murine muscle cells (15). On the other hand, some previous reports demonstrated that curcumin activates AMPK through LKB1 (15,25,23). Thus, the upstream kinase for curcumin-caused phosphorylation of AMPK is the chaotic situation. It needs further study about the molecular target of bisacurone in future.

**Abbreviations**

ACC acetyl-CoA carboxylase

References

1. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. *Hippokratia* 2009; 13: 9–19.
2. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* 2010; 51: 679–689.
3. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. *J Gastroenterol* 2013; 48: 434–441.
4. Newbery EP, Xie Y, Kennedy S, et al. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. *J Biol Chem* 2003; 278: 51664–51672.
5. Ismaiel A, Dumitruca DL. Cardiovascular risk in fatty liver disease: the liver-heart axis—literature review. *Front Med (Lausanne)* 2019; 6: 202.
6. Garcia D, Hellberg K, Chua A, et al. Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD. *Cell Rep* 2019; 26: 192–206.e6.
7. Kemp BE, Stapleton D, Campbell DJ, et al. AMP-activated protein kinase, super metabolic regulator. *Biochem Soc Trans* 2003; 31 (Pt 1): 162–168.
8. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate super metabolic regulator. *Nat Prod Commun* 2017; 12: 1325–1348.
9. Wang Q, Liu S, Zhai A, Zhang B, Tian G. AMPK-mediated regulation of lipid metabolism by phosphorylation. *Biopharm Bull* 2018; 41: 985–993.
10. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* 2002; 109: 1125–1131.
11. Ishi S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. *Proc Natl Acad Sci U S A* 2004; 101: 15597–15602.
12. Matsusue K, Gavrilova O, Lambert G, et al. Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of gluconeogenesis in leptin-deficient mice. *Mol Endocrinol* 2004; 18: 2751–2764.
13. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J Hepatol* 2015; 62: 720–733.
14. Jung EJ, Kwon SW, Jung BH, Oh SH, Lee BH. Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. *J Lipid Res* 2011; 52: 1617–1625.
15. Eigner D, Scholz D. Ferula asa-foetida and Curcuma longa in traditional medicine and treatment and diet in Nepal. *J Ethnopharmacol* 1999; 67: 1–6.
16. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, Ramirez-Tortosa M. Curcumin and health. *Molecules* 2016; 21: 264.
17. Kunnumakkara AB, Bordoloi D, Padmavathy G, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. *Br J Pharmacol* 2017; 174: 1325–1348.
18. Farzaei MH, Zobeiri M, Parvizi F, et al. Curcumin in liver diseases: a systematic review of the cellular mechanisms of oxidative stress and clinical perspective. *Nutrients* 2018; 10: pii: E8355.
19. Tomeh MA, Hadidianmrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. *Int J Mol Sci* 2019; 20: pii: E1033.

**Conflict of Interest**

No potential conflicts of interest were disclosed.
Curcuma longa) suppresses acute ethanol-induced liver injury in mice by inhibiting hepatic oxidative stress and inflammatory cytokine production. J Nutr Sci 2017; 6: e3.

37 Uchio R, Murosaki S, Ichikawa H. Hot water extract of turmeric (Curcuma longa) prevents non-alcoholic steatohepatitis in mice by inhibiting hepatic oxidative stress and inflammation. J Nutr Sci 2018; 7: e36.

38 Han Y, Hu Z, Cui A, et al. Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene. Nat Commun 2019; 10: 623.

39 Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376–388.

40 Zhang L, Li C, Wang F, et al. Treatment with PPARα agonist clofibrate inhibits the transcription and activation of SREBPs and reduces triglyceride and cholesterol levels in liver of broiler chickens. PPAR Res 2015; 2015: 347245.

41 Lee JH, Kang HS, Park HY, et al. PPARα-dependent Insig2a overexpression inhibits SREBP-1c processing during fasting. Sci Rep 2017; 7: 9958.

42 Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K. Mechanism for fatty acid “sparing” effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2002; 277: 3829–3835.

43 Iizuka K, Wu W, Horikawa Y, Saito M, Takeda J. Feedback looping between ChREBP and PPARα in the regulation of lipid metabolism in brown adipose tissues. Endocr J 2013; 60: 1145–1153.

44 Lee H, Kang R, Bae S, Yoon Y. AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/β-catenin pathway in 3T3-L1 adipocytes. Int J Mol Med 2011; 28: 65–71.

45 Bronner M, Hertz R, Bar-Tana J. Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor alpha by AMP-activated protein kinase. Biochem J 2004; 384 (Pt 2): 295–305.

46 Ravnskjær K, Boergesen M, Dalgaard LT, Mandrup S. Glucose-induced repression of PPARα gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation. J Mol Endocrinol 2006; 36: 289–299.

47 López M, Lage R, Saha AK, et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 2008; 7: 389–399.

48 McGarry JD, Leatherman GF, Foster DW. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J Biol Chem 1978; 253: 4128–4136.

49 Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 2013; 19: 1649–1654.

50 de Souza Teixeira AA, Souza CO, Biondo LA, et al. Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. Inflammopharmacology 2018; 26: 1103–1115.

51 Kim N, Kim HM, Lee ES, et al. Dibenzoylmethane exerts metabolic activity through regulation of AMP-activated protein kinase (AMPK)-mediated glucose uptake and adipogenesis pathways. PLoS One 2015; 10: e0120104.

52 Misra J, Chanda D, Kim DK, et al. Curcumin differentially regulates endoplasmic reticulum stress through transcriptional corepressor SMILE (small heterodimer partner-interacting leucine zipper protein)-mediated inhibition of CREBH (cAMP responsive element-binding protein H). J Biol Chem 2011; 286: 41972–41984.

53 Na LX, Zhang YL, Li Y, et al. Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis 2011; 21: 526–533.